title: Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells.
abstract: TINCR is a well-known lncRNA which acts as a master regulator in somatic differentiation development. However, it is still unclear whether TINCR is also involved in caner occurrence and progression. In this study, we observed that TINCR was up-regulated in bladder cancer tissues and cells and contributed to oncogenesis and cancer progression. Silencing TINCR expression inhibited cell proliferation and promoted apoptosis in vitro, indicating that TINCR may be the potential therapeutic target for treating bladder urothelial carcinoma. Thus we used the synthetic biology approach to create theophylline controllable RNAi-based genetic switches which silenced TINCR in a dosage-dependent manner. Both RNAi-OFF and ON switches can be used to quantitatively control the expression of TINCR in bladder cancer to suppress the progression of bladder cancer. These findings suggest that lncRNA-TINCR could promote bladder cancer development and progression and artificial control of its expression through inducible RNAi may represent a new kind of therapeutic strategy for treating human bladder cancer.
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.|Shantou University Medical College, Shantou 515041, Guangdong Province, People's Republic of China.
authors: Zhicong
authors: Z
authors: Chen
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Yuchen
authors: Y
authors: Liu
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.|Anhui Medical University, Hefei 230601, Anhui Province, People's Republic of China.
authors: Anbang
authors: A
authors: He
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Jianfa
authors: J
authors: Li
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Mingwei
authors: M
authors: Chen
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Yonghao
authors: Y
authors: Zhan
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Junhao
authors: J
authors: Lin
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Chengle
authors: C
authors: Zhuang
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Li
authors: L
authors: Liu
authors: Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai 200000, Shanghai, China.
authors: Guoping
authors: G
authors: Zhao
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.
authors: Weiren
authors: W
authors: Huang
authors: Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, People's Republic of China.|Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing, 100034, China.
authors: Zhiming
authors: Z
authors: Cai
mesh_terms: D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D062085:RNA, Long Noncoding / Q000096:biosynthesis / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering / Q000096:biosynthesis / Q000235:genetics; D013806:Theophylline / Q000494:pharmacology*; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy
chemical_list: D062085:RNA, Long Noncoding; D012334:RNA, Neoplasm; D034741:RNA, Small Interfering; C000618032:TINCR lncRNA, human; D013806:Theophylline